<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/1354C618-9C7F-4E90-97AE-2A04B4C8536D"><gtr:id>1354C618-9C7F-4E90-97AE-2A04B4C8536D</gtr:id><gtr:name>Cancer Research UK (CRUK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/8D55713A-87FD-4232-B50F-49BB01546C91"><gtr:id>8D55713A-87FD-4232-B50F-49BB01546C91</gtr:id><gtr:name>GE (General Electric Company)</gtr:name><gtr:address><gtr:line1>General Electric Company</gtr:line1><gtr:line2>3135 Easton Turnpike</gtr:line2><gtr:postCode>06828</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Cancer Biology</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/1354C618-9C7F-4E90-97AE-2A04B4C8536D"><gtr:id>1354C618-9C7F-4E90-97AE-2A04B4C8536D</gtr:id><gtr:name>Cancer Research UK (CRUK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/8D55713A-87FD-4232-B50F-49BB01546C91"><gtr:id>8D55713A-87FD-4232-B50F-49BB01546C91</gtr:id><gtr:name>GE (General Electric Company)</gtr:name><gtr:address><gtr:line1>General Electric Company</gtr:line1><gtr:line2>3135 Easton Turnpike</gtr:line2><gtr:postCode>06828</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/2D2946B4-FD8D-4331-BDDA-B4ABB54D672E"><gtr:id>2D2946B4-FD8D-4331-BDDA-B4ABB54D672E</gtr:id><gtr:firstName>Geoffrey</gtr:firstName><gtr:otherNames>Martin</gtr:otherNames><gtr:surname>Boxer</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/F2DB9C2D-384B-4E3D-AD18-2ABE79D28778"><gtr:id>F2DB9C2D-384B-4E3D-AD18-2ABE79D28778</gtr:id><gtr:firstName>Surinder</gtr:firstName><gtr:otherNames>Kanta</gtr:otherNames><gtr:surname>Sharma</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/BF81D215-FD85-45FC-8DC2-51A3B54A98BC"><gtr:id>BF81D215-FD85-45FC-8DC2-51A3B54A98BC</gtr:id><gtr:firstName>Barbara</gtr:firstName><gtr:surname>Pedley</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/E3A3EA72-8310-49ED-AB92-708593EA05FE"><gtr:id>E3A3EA72-8310-49ED-AB92-708593EA05FE</gtr:id><gtr:firstName>Timothy</gtr:firstName><gtr:surname>Meyer</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/29F35B45-0BF2-4F52-905E-552188EC64A7"><gtr:id>29F35B45-0BF2-4F52-905E-552188EC64A7</gtr:id><gtr:firstName>Kerry</gtr:firstName><gtr:otherNames>Ann</gtr:otherNames><gtr:surname>Chester</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G1001497"><gtr:id>3A4CA335-3D11-4707-95F8-92233325FC6A</gtr:id><gtr:title>Developing a novel therapy, combining RIT with conventional therapy, for treatment of advanced colorectal cancer</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1001497</gtr:grantReference><gtr:abstractText>Bowel cancer is the third most common cancer in the UK ( 38,000 new cases/year), with more than 50% of those patients eventually dying of their disease. Radioimmunotherapy (RIT), uses a man-made molecule that is exactly like an antibody that we would make to fight the bacteria that infect us sometimes, except it is designed to bind to foreign cancer cells rather than bacterial cells. The cancer targeting antibody can be linked to radioactivity and injected into the patient, where it becomes able to kill cancer cells wherever they are in the body. This method has been partly successful in some patients in clinical trials. However, the cancer sometimes regrows, because the antibody and radiation cannot get to all cells and some that are bombarded with radiation, seem to survive. It is not possible to inject more of the radiolabeled antibody as the increased radiation would also affect the cells in the bloodstream and our normal white cells that protect us from infection. Our previous research showed that when we combined RIT, with another antibody which also targets colorectal cancer, the effect of the radiation from the radiolabeled antibody increased, and animals with tumours were cured. We plan to experiment with the amount of the two antibodies, and the times that they are given, so that the schedule for the combined antibody therapy is ready to be given to patients as part of a clinical trial within 3 years.</gtr:abstractText><gtr:technicalSummary>Colorectal cancer is the third most common cancer in the UK ( 38,000 new cases/annum), with 50% mortality rates. Radioimmunotherapy (RIT), the use of antibodies for sustained targeting of therapeutic radionuclides to the tumour, increases specificity of treatment and reduces systemic toxicity. Using antibodies that bind to carcinoembryonicantigen (CEA), overexpressed in colorectal tumours, we have shown RIT responses in pre-clinical and clinical studies. However, tumours have a tendency to regrow, because of non-uniform radiation dose delivery to cancer cells, and their differential sensitivity to radioactivity. This is aggravated by both the heterogeneous microenvironment and mutated genotype of the cells, which affect how tumours respond to ionising radiation. This treatment failure necessitates a combination therapy to significantly enhance RIT radiation damage. We previously combined RIT with vascular disprupting agents clinically, and obtained partial responses in patients refractory to standard treatment. We propose combining a humanised 131I?labeled anti-CEA antibody with a second antibody that also targets colorectal cancer. This antibody enhances sensitivity of tumours to external beam radiation clinically, and significantly augments RIT in our own pre-clinical studies. We plan to optimise timing and dosing schedules for this combined antibody therapy, for easy translation into early phase clinical trial within 3 years</gtr:technicalSummary><gtr:fund><gtr:end>2014-07-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-11-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>799573</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs><gtr:artisticAndCreativeProductOutput><gtr:description>Multifluorescence images of the tumour microenvironment and antibody targeting.</gtr:description><gtr:id>15FA9F66-086C-481B-8A0B-7740B729523B</gtr:id><gtr:impact>Used as illustrations by the Wellcome Trust.</gtr:impact><gtr:title>Fluorescence microscopy images</gtr:title><gtr:type>Image</gtr:type><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:artisticAndCreativeProductOutput></gtr:artisticAndCreativeProductOutputs><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London (UCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Pharmacy London UCL</gtr:department><gtr:description>in vivo therapy testing of novel drugs</gtr:description><gtr:id>110190EF-527E-4957-B270-43DA5FFC7DDA</gtr:id><gtr:impact>This is a multi-disciplinary collaboration between Dept Pharmacy and Dept Oncology.

A publication of this work was published in 2015 :
Ohnmacht SA, Marchetti C, Gunaratnam M, Besser RJ, Haider SM,Di Vita G, Lowe HL, Mellinas-Gomez M, Diocou S, Robson M, ?poner J, Islam B, Pedley RB, Hartley JA &amp;amp; Neidle S. A G-quadruplex-binding compound showing anti-tumour activity in an in vivo model for pancreatic cancer. Scientific Reports: DOI: 10.1038/srep11385, 2015.</gtr:impact><gtr:partnerContribution>production of novel anti-cancer drugs</gtr:partnerContribution><gtr:piContribution>Cancer xenograft studies in mice to test efficacy of compounds</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GE Healthcare</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>research for GE Healthcare</gtr:description><gtr:id>2010013E-EC8E-4585-AFD9-D4E361542970</gtr:id><gtr:impact>Preliminary studies have been performed with GE and other UCL Departments (Chemistry and Medicine)</gtr:impact><gtr:partnerContribution>radiolabeling antibodies and scanning mice</gtr:partnerContribution><gtr:piContribution>testing new antibodies</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK (CRUK)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Comprehensive Cancer Imaging Centre (CCIC)</gtr:description><gtr:id>E43F0989-69DE-42CD-BDE9-16BAB3BD4FD1</gtr:id><gtr:impact>Output
Many Multidisciplinary Publications with myself as author eg:
Walker-Samuel et al 2011, 2013
Rajkumar et al, 2012
Yan et al 2013
Laufer et al, 2012

New Publications:
Richard J. Browning, Vineeth Rajkumar, R. Barbara Pedley, Robert J. Eckersley, Philip J. Blower. Prospects for enhancement of targeted radionuclide therapy of cancer using ultrasound. J Label Compd Radiopharm DOI: 10.1002/jlcr.3157 2013.

Eletheria Panagiotaki, Simon Walker-Samuel, Bernard Siow, S. Peter Johnson, Vineeth Rajkumar, R. Barbara Pedley, Mark F. Lythgoe, Daniel C. Alexander. Non-invasive quantification of solid tumour microstructure with VERDICT MRI. Cancer Res 74(70): 1902-1912, 2014. 

Juan M Funes, Rachel Kaufman, James M Flanagan, Stephen Henderson, Mathew Robson, R Barbara Pedley, Salvador Moncada and Chris Boshoff. Oncogenic transformation decreases Nrf2 expression favoring reactive oxygen species accumulation and poorer survival. Molecular Cancer, 13: 1-17, 2014.

Abdollah MR, Kalber T, Tolner B, Southern P, Bear JC, Robson M, Pedley RB, Chester, K. Prolonging the circulatory retention of SPIONs using dextran sulfate: in vivo tracking achieved by functionalisation with near-infrared dyes. Faraday Discuss, 175 pp. 41-58. 10.1039/c4fd00114a, 2014.

S.J. Strauss, P. Mistry, A. Mendoza, M. Robson, H. Holme, P. Nandabhiwat, B. Kwok, M. Qadir, R.B. Pedley, J.S. Whelan, P.H.B. Sorensen. 245 Chk1 is a potential novel therapeutic target that regulates cell survival and potentiates chemotherapy in osteosarcoma (OS) models. Eur J Cancer 50: 82-82, 2014.

Jathoul AP, Laufer J, Ogunlade O, Treeby B, Cox B, Zhang E, Johnson P, Pizzey AR, Philip B, Marafioti T, Lythgoe MF, Pedley RB, Pule M and Beard P. Deep in vivo photoacoustic imaging of mammalian tissues using a tyrosine-based genetic reported. Nature Photonics 9: 239-246, 2015 IF32.4

Rajkumar V, Goh V, Siddique M, Robson M, Boxer G,Cook GJR, Pedley RB. Novel application of texture analysis to SPECT images of 125I-A5B7 anti-CEA antibody localisation in metastatic colorectal cancer models: Correlation with histological microarchitecture and response to antivascular therapy. Br J Cancer 112: 1882-1887, 2015. 

Vassileva V, Rajkumar V, Mazzantini M, Robson M, Badar A, Sharma S, &amp;Aring;rstad E, Hochhauser D, Lythgoe MF, Boxer GM, Pedley RB. Significant therapeutic efficacy with combined radioimmunotherapy and cetuximab in pre-clinical models of colorectal cancer. J Nucl Med, 2015, doi:10.2967/jnumed.115.157362. 

Nunes JPM, Morais M, Vassileva V, Robinson E, Rajkumar V, Smith MEB, Pedley RB, Caddick S, Baker JR,
Chudasama V. Next generation maleimides (NGMs) enable delivery of potent, site-selectively modified antibody-drug conjugates (ADCs). ChemComm: DOI:10.1039/c5cc03557k, 2015. 

Ohnmacht SA, Marchetti C, Gunaratnam M, Besser RJ, Haider SM,Di Vita G, Lowe HL, Mellinas-Gomez M, Diocou S, Robson M, ?poner J, Islam B, Pedley RB, Hartley JA &amp;amp; Neidle S. A G-quadruplex-binding compound showing anti-tumour activity in an in vivo model for pancreatic cancer. Scientific Reports: DOI: 10.1038/srep11385, 2015. 

Goncalves M, Johnson S, Ramasawmy R, Pedley RB, Lythgoe M, Walker-Samuel S. Decomposition of spontaneous fluctuations in tumour oxygenation using BOLD MRI and independent component analysis. B J Cancer 113: 1168-1177, 2015

Mellinas-Gomez M, Spanswick VJ, Paredes Moscosso SR, Robson M, Pedley RB, Thurston DE, Baines SJ, Stell A and Hartley JA. Activity of the DNA minor groove cross-linking agent SG2000 (SJG-136) against canine tumours. BMC Veterinary Research, in press 2015. 8156928301564140

Outcome
New CCIC grant funding for 2013-2018 approx. &amp;pound;8 million</gtr:impact><gtr:partnerContribution>Multimodality live animal imaging by other UCL departments (Engineering, CABI, etc). 

Labeling of antibodies with radionuclides (UCL Dept. of Chemistry)</gtr:partnerContribution><gtr:piContribution>Co-investigator, managing all animal research into cancer therapy on the grant.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>poster presentation, NCRI Liverpool 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>08E16F95-6347-4981-8DE8-E10D712BC12A</gtr:id><gtr:impact>The poster sparked interest, questions and discussion

requests for publications</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>poster presentation</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>internatioal meeting (Vancouver, Canada)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3E536431-1442-4E93-8AA2-1015C4E5ABA9</gtr:id><gtr:impact>Contact from attendees concerning future collaborations, meetings and workshops.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>poster presentation</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>81A51D53-2C01-4038-B6E7-A83B24A6D449</gtr:id><gtr:impact>Stimulated thinking and questions

research contacts with other scientists</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>regular lecturing</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>ADF1E721-BE6E-4DFF-87A5-B3D4A051CA81</gtr:id><gtr:impact>Between 20 and 370 students attend these courses, and all finish with a robust question and discussion section.

From this we, and other groups within UCL, receive many applications for students to undertake projects in the lab, or to join my group as PhD students</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>2007,2008,2009,2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Tumour Microenvironment Meeting (Rhodes, Greece)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>87856D56-099E-47C4-A0BB-37509D6898B5</gtr:id><gtr:impact>Presented my research in a lecture to approx. 100 people at a scientific meeting. Many attendees expressed their interest in my work, and are still in contact.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Poster presentation NCRI Liverpool 2013</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A81B1DE0-96DD-4C96-BC80-9EBCE62A2A38</gtr:id><gtr:impact>Presentation sparked both many questions and discussions

Further discussions between related groups</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>Pre-2006,2006,2007,2008,</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CR UK CCIC annual meeting, London, 2016</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>C2A655BD-5EF0-44F1-BEA4-A74B4BDBA114</gtr:id><gtr:impact>Presented my research at the annual meeting of the UCL Cancer Research UK CCIC meeting. The audience was mainly composed of other scientists involved on this grant.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Study participants or study members</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>poster presentation</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>113E564E-5EDA-4104-A44E-81D95BB6F40D</gtr:id><gtr:impact>The presentation stimulated interest and questions from the delegates.

Continued contact with researchers in the same field of study.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Tumor Microenvironment Workshop, Miami</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>343CD482-2E9D-4678-B6D3-3141FF61FE9F</gtr:id><gtr:impact>Approx 60 fellow scientists attended the meeting, resulting in discussion and the setting up of joint projects.

Thirteenth Tumor Microenvironment Workshop 2013, Miami, Florida.
my Talk: Investigating tumour vasculature development and the effects of OXi4503 by non-invasive photoacoustic imaging. 



Visits form other scientists, and joint projects.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>Pre-2006,2006,2008,2010,</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>74797</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Bone Cancer Research Trust</gtr:description><gtr:end>2014-06-02</gtr:end><gtr:fundingOrg>Bone Cancer Research Trust</gtr:fundingOrg><gtr:id>5E20254A-4AD0-4921-87E8-4D8A9D51ECAD</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>346125</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Development pathway Funding Scheme ( DPFS) Co-investigator</gtr:description><gtr:end>2015-11-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>B8C3459E-8E57-4DCA-A25F-059F6B72D93F</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>8700000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Co-Investigator on Comprehensive Cancer Imaging Centre: joint KCL/UCL</gtr:description><gtr:end>2018-11-02</gtr:end><gtr:fundingOrg>Cancer Research UK (CRUK)</gtr:fundingOrg><gtr:id>5C3201C0-0A10-4298-9B57-1EEE9E5D14D9</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>New Agents Committee</gtr:description><gtr:end>2016-10-02</gtr:end><gtr:fundingOrg>Cancer Research UK (CRUK)</gtr:fundingOrg><gtr:id>9E35C408-E41C-437C-B179-6674C776C04D</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>99938</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>SBRI NC3Rs</gtr:description><gtr:end>2013-08-02</gtr:end><gtr:fundingOrg>National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs)</gtr:fundingOrg><gtr:id>5F9AF682-3398-4370-A665-FC394EA97636</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2013-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>831872</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EPSRC Research Grant, Standard Research, Co-I. TITLE: A new nano particulate vehicle for ultrasound enhanced delivery of Cisplatin</gtr:description><gtr:end>2017-08-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>EP/L026287/1</gtr:fundingRef><gtr:id>375173AB-19DB-4083-AE98-19FDAB1826C6</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>822532</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>DPFS</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/K025422/1</gtr:fundingRef><gtr:id>6215CAE2-D3D5-4148-83E4-B4DC5BBDE39F</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>126000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>DPFS</gtr:description><gtr:end>2014-07-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G1001497/1</gtr:fundingRef><gtr:id>F136566F-FD05-4F00-81E5-90EB4F712A81</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>40000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Rosetrees Trust</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>Rosetrees Trust</gtr:fundingOrg><gtr:id>4F7EC354-9792-4071-8F06-CB39F79DA0B2</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>20000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Rosetrees Foundation</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>Rosetrees Trust</gtr:fundingOrg><gtr:fundingRef>JS16/M265</gtr:fundingRef><gtr:id>B9B7A831-D54B-4568-98EC-89133FDDF119</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>GlucoCEST (glucose chemical exchange saturation transfer) is a noninvasive method for imaging glucose uptake in vivo that is based on magnetic resonance imaging and allows the uptake of unlabeled glucose to be measured through the chemical exchange of protons between hydroxyl groups and water. GlucoCEST differs from existing molecular imaging methods because it permits detection of the delivery and uptake of a metabolically active compound in physiological quantities. GlucoCEST, is sensitive to tumor glucose accumulation and can distinguish tumor types with differing metabolic characteristics and pathophysiologies suggesting that glucoCEST has potential as a useful and cost-effective method for characterizing disease and assessing response to therapy in the clinic.</gtr:description><gtr:id>54CEDE4C-D6E3-4DEB-B46C-322B49BEEC0D</gtr:id><gtr:impact>Obtained H2020 award (Xavier Golay) to translate GlucoCEST to the clinic.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>GlucoCEST</gtr:title><gtr:type>Physiological assessment or outcome measure</gtr:type><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Look-Locker FAIR-ASL-MRI has been to measure liver perfusion in a small animal setting. The reproducibility and repeatability of the technique was investigated within and between imaging sessions. A method of retrospective respiratory gating (PENIR) was introduced that is data driven, and was found to reduce the uncertainty in the perfusion estimate. Finally, HASL was applied to a mouse model of colorectal liver metastasis and showed a perfusion deficit within the tumours relative to the normal liver.</gtr:description><gtr:id>7DC8D1B4-93FB-4590-8F06-0D38C2A47B0F</gtr:id><gtr:impact>none at present</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Hepatic arterial spin labelling MRI (hASL) MRI</gtr:title><gtr:type>Physiological assessment or outcome measure</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>VERDICT is an innovative MRI method that can reveal new non-invasive markers of cancer pathology. In particular it develops biophysical models of tumour tissue that support non-invasive estimates of key characteristics of tissue cellular architecture including those that currently guide diagnosis, grading, and treatment assignment through classical histology.</gtr:description><gtr:id>2049918F-9C38-42EA-B6BD-E501BA78731A</gtr:id><gtr:impact>VERDICT has undergone a first in Man study and is now in medium size clinical trial of 350 patients</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>VERDICT MRI</gtr:title><gtr:type>Physiological assessment or outcome measure</gtr:type><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/28095DA5-83D4-4026-BD0A-FE18A217F64A"><gtr:id>28095DA5-83D4-4026-BD0A-FE18A217F64A</gtr:id><gtr:title>Deep in vivo photoacoustic imaging of mammalian tissues using a tyrosinase-based genetic reporter</gtr:title><gtr:parentPublicationTitle>Nature Photonics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/967681067dff2cd4b0f86dd0b53081c5"><gtr:id>967681067dff2cd4b0f86dd0b53081c5</gtr:id><gtr:otherNames>Jathoul A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B7068F53-86B0-42DB-A6CE-8DD3E19204E4"><gtr:id>B7068F53-86B0-42DB-A6CE-8DD3E19204E4</gtr:id><gtr:title>Adrenomedullin haploinsufficiency predisposes to secondary lymphedema.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5cb2851bdeb567cd79ef5ffe4edb122d"><gtr:id>5cb2851bdeb567cd79ef5ffe4edb122d</gtr:id><gtr:otherNames>Nikitenko LL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D8A6F55E-A0D7-4BC0-AC2D-239F59FC61CF"><gtr:id>D8A6F55E-A0D7-4BC0-AC2D-239F59FC61CF</gtr:id><gtr:title>Functional native disulfide bridging enables delivery of a potent, stable and targeted antibody-drug conjugate (ADC).</gtr:title><gtr:parentPublicationTitle>Chemical communications (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/53ad80b0f6f78f1f483527d5a3124bb1"><gtr:id>53ad80b0f6f78f1f483527d5a3124bb1</gtr:id><gtr:otherNames>Nunes JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1359-7345</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EED42EF9-A2CF-4524-967C-EA088DBA697F"><gtr:id>EED42EF9-A2CF-4524-967C-EA088DBA697F</gtr:id><gtr:title>In vivo imaging of glucose uptake and metabolism in tumors.</gtr:title><gtr:parentPublicationTitle>Nature medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/cd64dc58efa1cf7a3649046a9b81512c"><gtr:id>cd64dc58efa1cf7a3649046a9b81512c</gtr:id><gtr:otherNames>Walker-Samuel S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1078-8956</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E1BA398D-E13D-427E-B757-26FFDB79A58C"><gtr:id>E1BA398D-E13D-427E-B757-26FFDB79A58C</gtr:id><gtr:title>Activity of the DNA minor groove cross-linking agent SG2000 (SJG-136) against canine tumours.</gtr:title><gtr:parentPublicationTitle>BMC veterinary research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5d0b06864c384c98da3706891bf16ad6"><gtr:id>5d0b06864c384c98da3706891bf16ad6</gtr:id><gtr:otherNames>Mellinas-Gomez M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1746-6148</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/64AE8A85-827A-48AE-8590-DA0043DDE171"><gtr:id>64AE8A85-827A-48AE-8590-DA0043DDE171</gtr:id><gtr:title>A comparative study of PDGFR inhibition with imatinib on radiolabeled antibody targeting and clearance in two pathologically distinct models of colon adenocarcinoma.</gtr:title><gtr:parentPublicationTitle>Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ca1506946cee358a0a61887738911fc6"><gtr:id>ca1506946cee358a0a61887738911fc6</gtr:id><gtr:otherNames>Rajkumar VS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1010-4283</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8BECFD5C-091C-4AA7-AB90-1FC387B30949"><gtr:id>8BECFD5C-091C-4AA7-AB90-1FC387B30949</gtr:id><gtr:title>A one-pot three-component radiochemical reaction for rapid assembly of 125I-labeled molecular probes.</gtr:title><gtr:parentPublicationTitle>Journal of the American Chemical Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/04b9849be2f79193588c4e2c546f507c"><gtr:id>04b9849be2f79193588c4e2c546f507c</gtr:id><gtr:otherNames>Yan R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0002-7863</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A91AD5C7-B39F-4D2B-9000-EFFE66B5CFF3"><gtr:id>A91AD5C7-B39F-4D2B-9000-EFFE66B5CFF3</gtr:id><gtr:title>Noninvasive quantification of solid tumor microstructure using VERDICT MRI.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/50e7224a737e5ef6230d0dba2a9221bf"><gtr:id>50e7224a737e5ef6230d0dba2a9221bf</gtr:id><gtr:otherNames>Panagiotaki E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3F57EF0D-A03B-4EAF-BEF3-480AD27FDC7C"><gtr:id>3F57EF0D-A03B-4EAF-BEF3-480AD27FDC7C</gtr:id><gtr:title>Human CHCHD4 mitochondrial proteins regulate cellular oxygen consumption rate and metabolism and provide a critical role in hypoxia signaling and tumor progression.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1c4df4241d0e1193d5aeffe9e19aab3d"><gtr:id>1c4df4241d0e1193d5aeffe9e19aab3d</gtr:id><gtr:otherNames>Yang J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7C675736-AE2D-45FE-9C66-4052760C74C6"><gtr:id>7C675736-AE2D-45FE-9C66-4052760C74C6</gtr:id><gtr:title>In vivo preclinical photoacoustic imaging of tumor vasculature development and therapy.</gtr:title><gtr:parentPublicationTitle>Journal of biomedical optics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/246c6cc0822c8329e15b30836364ebb4"><gtr:id>246c6cc0822c8329e15b30836364ebb4</gtr:id><gtr:otherNames>Laufer J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1083-3668</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B048A1B3-94B1-4CEB-960D-A3BCC8EDEBD4"><gtr:id>B048A1B3-94B1-4CEB-960D-A3BCC8EDEBD4</gtr:id><gtr:title>Deep in vivo photoacoustic imaging of mammalian tissues using a tyrosinase-based genetic reporter</gtr:title><gtr:parentPublicationTitle>Nature Photonics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/967681067dff2cd4b0f86dd0b53081c5"><gtr:id>967681067dff2cd4b0f86dd0b53081c5</gtr:id><gtr:otherNames>Jathoul A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4F966351-041D-4CC3-B65B-7F263DBD4757"><gtr:id>4F966351-041D-4CC3-B65B-7F263DBD4757</gtr:id><gtr:title>Significant Therapeutic Efficacy with Combined Radioimmunotherapy and Cetuximab in Preclinical Models of Colorectal Cancer.</gtr:title><gtr:parentPublicationTitle>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7af4d9d0cc1697d0e18c8a1d521ba2b4"><gtr:id>7af4d9d0cc1697d0e18c8a1d521ba2b4</gtr:id><gtr:otherNames>Vassileva V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0161-5505</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9E8CBBC1-5218-4E6C-9694-0DC9F8BF395F"><gtr:id>9E8CBBC1-5218-4E6C-9694-0DC9F8BF395F</gtr:id><gtr:title>A G-quadruplex-binding compound showing anti-tumour activity in an in vivo model for pancreatic cancer.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1fa01e6c47c2d7880aef1437711c3be5"><gtr:id>1fa01e6c47c2d7880aef1437711c3be5</gtr:id><gtr:otherNames>Ohnmacht SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7C1F18CE-8A95-4AD6-A99E-C3CB3594C4E9"><gtr:id>7C1F18CE-8A95-4AD6-A99E-C3CB3594C4E9</gtr:id><gtr:title>Decomposition of spontaneous fluctuations in tumour oxygenation using BOLD MRI and independent component analysis.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ec25808315399ea0591f77d4c3a4f6e6"><gtr:id>ec25808315399ea0591f77d4c3a4f6e6</gtr:id><gtr:otherNames>Gon?alves MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/74D2D1DB-214B-4DF1-95AE-811EA182D8A1"><gtr:id>74D2D1DB-214B-4DF1-95AE-811EA182D8A1</gtr:id><gtr:title>Prospects for enhancement of targeted radionuclide therapy of cancer using ultrasound.</gtr:title><gtr:parentPublicationTitle>Journal of labelled compounds &amp; radiopharmaceuticals</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/964adae262514ba94f350c461de1d54f"><gtr:id>964adae262514ba94f350c461de1d54f</gtr:id><gtr:otherNames>Browning RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0362-4803</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3AC84C88-260B-4482-976F-253619408531"><gtr:id>3AC84C88-260B-4482-976F-253619408531</gtr:id><gtr:title>Acute changes in liver tumour perfusion measured non-invasively with arterial spin labelling.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1992cc9a6757f022ae884f1669c587aa"><gtr:id>1992cc9a6757f022ae884f1669c587aa</gtr:id><gtr:otherNames>Johnson SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/949E6147-658C-41AF-A391-6ED9D3D60105"><gtr:id>949E6147-658C-41AF-A391-6ED9D3D60105</gtr:id><gtr:title>Texture analysis of (125)I-A5B7 anti-CEA antibody SPECT differentiates metastatic colorectal cancer model phenotypes and anti-vascular therapy response.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f9a419a54250b786868647fd5185611f"><gtr:id>f9a419a54250b786868647fd5185611f</gtr:id><gtr:otherNames>Rajkumar V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/312387ED-7489-441F-B1FC-C7C788462C34"><gtr:id>312387ED-7489-441F-B1FC-C7C788462C34</gtr:id><gtr:title>Monitoring the Growth of an Orthotopic Tumour Xenograft Model: Multi-Modal Imaging Assessment with Benchtop MRI (1T), High-Field MRI (9.4T), Ultrasound and Bioluminescence.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ff3144312ff07b6ae140f7956468a077"><gtr:id>ff3144312ff07b6ae140f7956468a077</gtr:id><gtr:otherNames>Ramasawmy R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BC44BD4D-EAE7-4F75-9593-C868C019DCAE"><gtr:id>BC44BD4D-EAE7-4F75-9593-C868C019DCAE</gtr:id><gtr:title>Decomposition of spontaneous fluctuations in tumour oxygenation using BOLD MRI and independent component analysis.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ec25808315399ea0591f77d4c3a4f6e6"><gtr:id>ec25808315399ea0591f77d4c3a4f6e6</gtr:id><gtr:otherNames>Gon?alves MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1001497</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>006DC612-6329-4D37-A540-5FB2CA634720</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.5  Radiotherapy</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>